-- With growing interest in ADC development all over, Creative Biolabs, through an expansion to its portfolio of tumor targets, has announced new antibody development capabilities for three high-value solid tumor targets: DLL3, PTK7, and FAP. This expansion adds multiple dimensions of ADC target resources—tumor cells, tumor stemness, and the tumor microenvironment (TME)—supporting researchers and biopharmaceutical companies as they build the next generation of precision therapies.
In ADC development, the choice of target has increasingly become a pivotal determinant of clinical advancement. With a growing shift from traditional hematologic cancers to solid tumors, over half of which historically display little or no responses to treatment, new targets with high selectivity and strong internalization capacity are increasingly attracting interest.
Among them, DLL3—known for its highly tumor-specific expression in small cell lung cancer (SCLC) and neuroendocrine tumors—has long been recognized as a strong candidate for ADC development. To help researchers improve early-stage target assessment and antibody screening efficiency, the company has upgraded its related research modules and officially launched its DLL3 antibody development solution.
"One of the reasons DLL3 seems to be back in the spotlight is its distinctive expression pattern," remarked a scientist focused on the ADC platform at Creative Biolabs. "We're supporting an increasing number of clients who are investigating DLL3 antibodies that have improved internalization and potential ADC application, which will ultimately provide a breakthrough for solid tumors."
At the same time, the company has introduced antibody development capabilities for PTK7. As an atypical receptor tyrosine kinase highly expressed in colorectal cancer, gastric cancer, and multiple drug-resistant tumors, PTK7 is widely regarded as a promising ADC target. Creative Biolabs has optimized its antibody screening and cellular internalization validation workflows to help clients generate anti-PTK7 antibodies with improved affinity and specificity.
"PTK7's value lies not only in its broad expression across malignant tumors," a senior researcher commented, "but also in its role in regulating tumor invasiveness and the Wnt signaling pathway, making it a strong candidate for differentiated ADC development."
Notably, the expansion also includes FAP, a representative TME-related target. Abundantly expressed on cancer-associated fibroblasts (CAFs), FAP has become an important entry point for ADC strategies aimed at overcoming physical barriers in solid tumors. Unlike traditional tumor-cell-centric approaches, FAP-targeting ADCs may remodel the tumor stroma and improve drug penetration, thereby enhancing therapeutic synergy.
"The combination of DLL3, PTK7, and FAP represents a strategic expansion informed by our long-standing experience in ADC services," a Creative Biolabs expert stated. He further noted that, as the global ADC market rapidly grows, multi-target strategies will become an important way for biopharma companies to build competitive differentiation.
About
Through this expanded target portfolio, Creative Biolabs hopes to provide more support for partners across early ADC research, lead antibody screening, engineering optimization, and pharmacological evaluation, helping to speed progress during the pipeline process.
Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Website: https://www.creative-biolabs.com/adc/
Release ID: 89176733
Google
RSS